根治性前列腺切除术后延迟出现可检测PSA的自然病史
回顾性分析2000至2022年加州大学旧金山分校3348例接受根治性前列腺切除术的临床局限性前列腺癌患者,其中2868例术后PSA不可检测,642例在中位25个月出现延迟可检测PSA。延迟可检测PSA者10年无转移生存率92%、前列腺癌特异性死亡率3%、全因死亡率6%,即使未接受挽救治疗也可能有良好长期结局。
要点
- 术后6个月后延迟出现可检测PSA者10年无转移生存率92%、前列腺癌特异性死亡率3%、全因死亡率6%。
- 延迟可检测PSA者46%在术后10年内接受挽救治疗,中位PSA为0.08 ng/mL(IQR 0.05,0.14)。
- 高CAPRA-S评分(HR 1.09,CI 1.02-1.17,p=0.02)和PSA倍增时间<6个月(HR 7.58,CI 5.42-10.6,p<0.01)与接受挽救治疗相关。
核心结论
- 术后超过6个月出现可检测PSA的男性即使未接受挽救治疗也可能有良好的长期结局。
研究设计与样本
- 回顾性分析2000至2022年在加州大学旧金山分校接受根治性前列腺切除术的临床局限性前列腺癌男性。
- 从3348例患者中识别出2868例术后PSA不可检测者,其中642例在中位25个月(IQR 15,43)出现延迟可检测PSA,术后中位随访72个月。
- 主要结局为生化复发,定义为术后6个月起连续2次PSA≥0.03 ng/mL;次要结局包括挽救治疗、挽救治疗后治疗、无转移生存率(MFS)、前列腺癌特异性死亡率(PCSM)和全因死亡率(ACM)。
- 将该队列与先前描述的术后PSA立即检测队列进行比较。
主要发现
- 延迟可检测PSA者中65.7%在失败时PSA<0.10 ng/mL。
- 延迟可检测PSA者中46%在术后10年内接受挽救治疗,挽救治疗时中位PSA为0.08 ng/mL(IQR 0.05,0.14)。
- 高CAPRA-S评分(HR 1.09,CI 1.02-1.17,p=0.02)和PSA倍增时间<6个月(HR 7.58,CI 5.42-10.6,p<0.01)与接受挽救治疗相关。
- 挽救治疗后62%的男性在10年内出现复发性PSA失败。
- 总体10年MFS为92%、PCSM为3%、ACM为6%;因复发性PSA失败接受三级治疗者10年MFS为54%、PCSM为23%、ACM为23%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Men with a detectable PSA after radical prostatectomy (RP) are often offered salvage therapy while those with an undetectable PSA are monitored. We aim to better characterize the natural history of men with an initially undetectable PSA who subsequently developed a detectable PSA > 6 months after RP. METHODS: Retrospective analysis of men who underwent RP for clinically localized prostate cancer at the University of California, San Francisco from 2000 to 2022. The primary outcome was biochemical recurrence, defined as 2 consecutive PSA > = 0.03 ng/mL starting 6 months after surgery. Secondary outcomes were salvage treatment, post-salvage treatment, metastasis free survival (MFS), prostate cancer specific mortality (PCSM), and all-cause mortality (ACM). This cohort was compared to a previously described cohort who had an immediately detectable post-operative PSA. RESULTS: From our cohort of 3348 patients, we identified 2868 men who had an undetectable post-op PSA. Subsequently, 642 men had a delayed detectable PSA at a median of 25 months (IQR 15, 43) with median follow-up of 72 months after RP. PSA at time of failure was <0.10 ng/mL for 65.7% of men. Of those with a delayed detectable PSA, 46% underwent salvage treatment within 10 years after RP at a median PSA of 0.08 ng/mL (IQR 0.05, 0.14). High CAPRA-S score (HR 1.09, CI 1.02-1.17, p = 0.02) and PSA doubling time (PSA-DT) of <6 months (HR 7.58, CI 5.42-10.6, p < 0.01) were associated with receiving salvage treatment. After salvage treatment, 62% of men had recurrent PSA failure within 10 years. Overall, MFS was 92%, PCSM 3%, and ACM 6% at 10 years. For those who received tertiary treatment for recurrent PSA failure, MFS was 54%, PCSM 23% and ACM 23% at 10 years' time. CONCLUSIONS: Men who develop a detectable PSA > 6 months post-operatively may have excellent long-term outcomes, even in the absence of salvage therapy.
引用
- Szymaniak JA, Washington SL, Cowan JE, et al. The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis. 2023. PMID: 36765111. doi:10.1038/s41391-022-00638-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。